Managing Diabetic Macular Edema With an Eye on Inflammation

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Karl G. Csaky, MD, PhD; Anat Loewenstein, MD; Christina Y. Weng, MD, MBA
Release Date: 1/26/2022Expiration Date: 1/25/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1.25
Content Type: LectureProvider:
Pinnacle clinical studies have demonstrated significant visual and anatomical improvements when integrating anti-vascular endothelial growth factor therapies into management protocols for patients with diabetic macular edema (DME). However, in real-world practice, these results cannot always be reproduced due to treatment burden, lack of adherence, undertreatment, and incomplete response to these therapies. Evaluation of the aqueous and vitreous humor of patients with DME has identified a number of inflammatory cytokines whose concentrations closely correlate with the pathogenesis and severity of DME, serving as molecular targets for therapy. Intravitreal corticosteroids have been used to treat DME due to their ability to inhibit several cytokines and chemokines while reducing retinal neovascularization and permeability. In this CME activity, experts in the field discuss the current unmet needs in the overall management and care of patients with DME, examine anatomical and clinical biomarkers that highlight the role of cytokines in DME severity and treatment response, and assess the current evidence regarding the targeting of inflammation in DME to achieve better vision outcomes.